IceCure Medical Ltd.: Business Overview, Financials & Competitive Analysis
IceCure Medical Ltd. scores 3/10 on the AskCyborg Cyborg Score (Weak). Early-stage cryoablation innovator with proven technology but minimal market traction and significant capitalization pressure. As of March 18, 2026, IceCure's stock price was $0.6001 with a market capitalization of approximately $50.3 million. The company received Nasdaq minimum bid price non-compliance notification in July 2024, requiring shares to maintain at.
What is IceCure Medical Ltd.'s industry? IceCure Medical Ltd. (icecure-medical.com) operates in Medical Devices. AskCyborg classifies IceCure Medical Ltd. under Medical Devices in its company registry.
IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems designed to destroy benign and cancerous tumors by freezing them as a minimally invasive option to surgical tumor remova...
Cyborg Score thesis
Early-stage cryoablation innovator with proven technology but minimal market traction and significant capitalization...
Read the full analyst-debate transcript →Get the Latest IceCure Medical Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeIceCure Medical Ltd. Overview
Pro stress-test →IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems designed to destroy benign and cancerous tumors by freezing them as a minimally invasive option to surgical tumor removal. The company's primary focus areas include breast, kidney, bone, and lung cancer, and its technology is intended to be performed in relatively short procedures.
Strategic Profile
Pro stress-test →The company's flagship product is the ProSense® Cryoablation System, described as a minimally invasive cryosurgical tool that uses liquid nitrogen to create large lethal zones for tumor destruction. The commercial-stage company markets its systems and technologies internationally, with presence in the United States, Japan, India, China, Israel, and other markets.
Competitive Landscape
Pro stress-test →Investors comparing IceCure often look at related companies in the medical devices sector, including Pulmonx Corp (LUNG), Volitionrx (VNRX), Baird Medical (BDMD), Apyx Medical Corporation (APYX), and Tela Bio, Inc. (TELA). IceCure's cryoablation technology positions it as a niche player in minimally invasive tumor treatment, competing against both traditional surgical approaches and alternative ablation technologies.
Industry Context
IceCure Medical Ltd. operates in Medical Devices.
Key facts
Founded: 2006 · Headquarters: Caesarea, Israel · Employees: N/A · Revenue: N/A · Market cap: $50.3M